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Introduction
The recombinant adeno-associated viruses (rAAVs) are 
powerful gene delivery vehicles for long-term, cell type-
specific gene expression in living animals.1,2 Previously, 
we deployed the rAAV technology to deliver genetically 
encoded activity sensors to optically record neuronal activ-
ity in selected brain regions.3,4 Further, we have applied 
the rAAVs to inducibly delete a specific gene in a selective 
brain region,5,6 thereby linking gene function(s) with learn-
ing-dependent synaptic plasticity5 and memory formation.5 
With AAVs, after virus infection in cells, maximum trans-
gene expression can be observed in a matter of 2 weeks, 
both in vitro6 and in vivo.6 The flexibility to engineer designer 
rAAVs with different capsid proteins7 is an added advantage 
for selective targeting of diverse cell types. The rAAV DNA 
exit in the cell nucleus as episomal concatemers,8 and, in 
some cases, it can integrate at a specific DNA site in the 
host genome,9 without any observable side effects. Impor-
tantly, rAAVs are largely nonpathogenic,10,11 which make 
them very attractive gene delivery vehicles for human gene 
therapy. Indeed, promising results have been reported with 
rAAVs to treat a number of diseases, including Leber’s Con-
genital Amaurosis,12 Hemophilia,13 congestive heart fail-
ure,14 and Parkinson’s disease.15
Our rAAVs are equipped with tetracycline (tet)-controlled 
genetic switches for inducible and reversible control of gene 
expression6 in any brain region(s) and cell type of choice, and 
gene expression can be controlled by doxycycline (Dox) at 
any time point chosen by an experimentalist. The use of rAAVs 
equipped with the tet inducible genetic switches thus paves 
the way to link gene activity to neuronal circuit function(s) 
in complex biological processes such as learning and mem-
ory,16 emotion,17 addiction,18 stress/anxiety,19 depression,20 
pain,21 and aging.22 Here, we have characterized the differ-
ent parameters for reliable control gene expression in the 
mammalian brain using a two-virus approach equipped with 
the tTA (Tet-off) and rtTA (Tet-on) systems. Importantly, to 
combat various neurological disorders and malfunctions, our 
two rAAV approach is suitable for gene therapy.
Results
Tet-controlled gene expression in vitro and in vivo
There are two complementary tetracycline (tet) inducible 
 systems,23,24 which are based on three key components 
(Figure 1a,b): (i) a tet transactivator (tTA)25 or a reverse tTA 
(rtTA),26,27 which are potent synthetic transcriptional factors, 
(ii) a unidirectional minimal tet promoter (Ptet)
25 or a bidi-
rectional minimal tet promoter (Ptetbi)
28 to express multiple 
gene(s) of interest, when either tTA or rtTA binds to the tet 
operators (tetO)s located in Ptet/Ptetbi, and (iii) an inducer, 
doxycycline (Dox), a hydrophobic derivative of tet that con-
trols gene expression and can rapidly distribute in different 
tissues in vivo, and easily crosses the blood–brain barrier.29 
The operating principle of the tet systems (Figure 1c) is as 
follows: in the absence of Dox, tTA binds to the tetOs located 
in Ptet/Ptetbi to activate gene transcription, and in the pres-
ence of Dox, gene transcription can be switched-off, when 
the tTA/Dox complex unbinds the tet promoters (Ptet/Ptetbi). 
The reverse tTA (rtTA) variants binds to Ptet/Ptetbi only in the 
presence of Dox (rtTA/+Dox) to activate Ptet/Ptetbi mediated 
gene transcription, and without Dox, rtTA is unable to bind 
Ptet/Ptetbi, thereby terminating gene transcription.
We have developed recombinant rAAVs to inducibly and 
reversibly control gene expression in the mammalian brain. 
With our two-virus approach, we placed tTA or rtTA under 
control of a pan-neuronal specific promoter (human synap-
sin or hSYN) (Figure 1a,b). For quantifying gene expression, 
we placed the firefly luciferase (fLUC)30 and the tdTomato 
(tdTOM)6,31 genes under control of a Ptetbi  (Figure 1a–c). With 
Ptetbi, these two genes were coexpressed for (1) live fluores-
cence imaging of neurons with tdTOM and (2) quantitative 
recording of luciferase (LUC) activity (Figure 1a,b). To normal-
ize for the variability in gene expression, which is largely due to 
variability in virus infection of cells, we included a “tracer” virus 
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to express the renilla luciferase (rLUC) in neurons. The use of 
specific light-emitting substrates for fLUC and rLUC, D-luciferin 
and coelenterazine, respectively, enabled us to quantify gene 
expression in a ratiometric manner (fLUC/rLUC) (Figure 2b), 
which are displayed here as relative light units (RLU) ± SEM.
First, we infected hippocampal organotypic slices with a 
cocktail of two rAAVs: tTA system (rAAV-hSYN-tTA2 + rAAV-
Ptetbi-fLUC/tdTOM) and rtTA system (rAAV-hSYN-rtTA2-nM2 
+ rAAV-Ptetbi-fLUC/tdTOM). Two weeks after virus infection, 
we detected robust Dox-induced, rtTA-dependent and tTA-
dependent tdTOM expression (Figure 2a, middle and right 
 panels). Expression of tdTOM was undetectable without 
Dox  (Figure 2a, left panel). Because the half-life time of 
the tdTOM protein is about 24 hours, it takes several days to 
deplete the tdTOM signal, when using the tTA system after 
Dox treatment (data not shown).
The fLUC on the other hand has a half-life time of only 
a few hours, enabling determination of Dox-controlled, tTA/
rtTA dependent gene expression time course, both in vitro 
and in vivo. To quantify gene expression, we performed the 
LUC assays using a cocktail of three viruses; the tTA system 
(rAAV-hSYN-tTA2 + rAAV-Ptetbi-fLUC/tdTOM + rAAV-hSYN-
rLUC) and the rtTA system (rAAV-hSYN-rtTA2-nM2 + rAAV-
Ptetbi-fLUC/tdTOM + rAAV-hSYN-rLUC). With the tTA system, 
RLU activity was about 18-fold higher over the baseline (with-
out tTA or with tTA/+Dox). In the case of the rtTA system, the 
RLU activity without Dox was near the baseline levels, and 
RLU activity increased by about 20-fold by Dox (Figure 2b). 
We further demonstrated by NeuN immunostaining that the 
hSYN promoter allows for neuron-specific gene expression 
both in vitro and in vivo (Supplementary Figure S1).
The raw firefly luciferase (fLUC) activity values in brain tis-
sue (both in vitro and in vivo), infected with the rAAV-Ptetbi-
fLUC/tdTOM alone (without tTA), were roughly 10 times higher 
than the background values (lysate without virus infection) 
(Supplementary Figure S2). Similarly, raw fLUC activity val-
ues with the rtTA system in the absence of Dox were roughly 
10 times higher than the background fLUC activity (without 
virus infection) (Supplementary Figure S2). The observed 
basal fLUC activity in the uninduced state is thus most likely 
due to the intrinsic leakiness by the tet responder virus (rAAV-
Ptetbi-fLUC/tdTOM), and leakiness increases with increasing 
number of rAAV-Ptetbi virus particles in infected cells. Con-
sistent with our previous observations,6 intrinsic leakiness by 
rAAV-Ptetbi module is likely mediated by the rAAV inverted ter-
minal repeat (ITR) enhancer-like activity onto the Ptetbi.
32 To 
reduce leakiness, we had to lower the rAAV-Ptetbi virus titers
We also performed noninvasive bioluminescence imaging 
with the tet inducible systems using the enhanced firefly lucif-
erase (eLUC), but the eLUC activity was not detected in the 
mouse brain through an intact skull (data not shown). How-
ever, strong bioluminescence signal was detected through 
an intact skull, skin and fur with the mouse cortex injected 
with rAAV-hSYN-eLUC (Figure 2c). We further determined 
that the maximum eLUC activity from brain samples infected 
with the rAAV-hSYN-eLUC was quite similar to brain samples 
infected with the Tet-inducible systems (rAAV-hSYN-tTA2 + 
rAAV-Ptetbi-eLUC/Venus, -Dox and rAAV-hSYN-rtTA2-nM2 + 
rAAV-Ptetbi-eLUC/Venus, +Dox) (Supplementary Figure S3). 
In the case of the inducible systems, the low virus titer (rAAV-
Ptetbi-eLUC/Venus) hindered signal detection from the intact 
skull. However, the eLUC signal was detected, when the skull 
was removed (data not shown). We propose that in future 
studies long-term regulated gene expression in mouse brain 
should be feasible by noninvasive in vivo bioluminescence 
imaging. We further suggest that noninvasive in vivo biolumi-
nescence imaging using the rAAV-hSYN-eLUC can serve as 
a reliable tool to control for the variability in virus injection and 
will help to identify properly rAAV-injected animals.
Repetitive ON/OFF gene expression cycles in vitro
Because access and removal of Dox occurs rapidly in cul-
tured cells, we used dissociated neurons as a model system 
to investigate the time course of tTA-dependent gene expres-
sion inactivation by Dox and re-activation upon Dox removal 
and rtTA-dependent gene expression activation by Dox and 
Figure 1  The rAAV constructs. (a) Three viral vectors shown here; the reverse tetracycline transactivator (rtTA2-nM2) under control of a 
human synapsin promoter (hSYN), a bidirectional tetracycline promoter (Ptetbi) driving expression of two genes, firefly luciferase (fLUC) and 
tdTomato (tdTOM), in opposite orientations and the renilla luciferase (rLUC) under control of the hSYN promoter. (b) Same as (a) except that 
tetracycline transactivator (tTA) is under control of the hSYN promoter. (c) Turning gene expression ON and OFF using either the tTA system 
or the rtTA system. With the tTA system, Ptetbi is ‘ON’ because tTA binds to Ptetbi and gene expression is switched-OFF in the presence of Dox. 
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inactivation upon Dox removal. In these experiments, we 
applied a three virus cocktail: the tTA system (rAAV-hSYN-
tTA2 + rAAV-Ptetbi-fLUC/tdTOM + rAAV-hSYN-rLUC) and 
the rtTA system (rAAV-hSYN-rtTA2-nM2 + rAAV-Ptetbi-fLUC/
tdTOM + hSYN-rLUC). Two weeks after virus infection, neu-
rons were treated with Dox in the medium and RLU activity 
was calculated at various time points. After Dox treatment for 
24 hours, RLU activity with the tTA and rtTA systems reached 
a baseline and a maximum, respectively, and it remained 
nearly unchanged after an additional 24 hours (Figure 3a,b). 
Further, Dox-controlled on/off gene expression cycles with 
the tTA and rtTA systems were possible with an interval of 48 
hours. These experiments were performed by separating the 
virus-treated primary dissociated neurons into four groups (n 
= 4 per group, each group) lasting six days and RLU activity 
was measured from cell lysates. With the tTA and rtTA sys-
tems over a period of 6 days, the magnitude of RLU activity 
regulation was 10- and 12-fold, respectively (Figure 3c,d).
Repetitive ON/OFF gene expression cycles in vivo
To determine an optimal Dox concentration required to switch-
off and switch-on gene expression in tTA and rtTA-dependent 
manner, respectively, we injected a three-virus cocktail bilat-
erally into cortex and hippocampus of 10 wild-type mice. Two 
weeks after virus injection, mice were treated with different 
concentrations of Dox (3, 10, 30, and 100 μg/g body weight, 
n = 2 mice per group). Two days after intraperitoneal (i.p.) 
Dox injection, RLU activity was measured from virus injected 
brain lysates (four samples per mouse, i.e., cortices and 
 hippocampi of both brain hemispheres). With the tTA system, 
10 and 100 μg/g body weight of Dox reduced gene expres-
sion levels by 7- and 10-fold, respectively (Figure 4a). With 
the rtTA system, however, 30 and 100 μg/g body weight of 
Dox increased gene expression by 13- and 16-fold, respec-
tively (Figure 4b).
To determine the number of days required for gene reac-
tivation after a single i.p. Dox injection (with tTA) and gene 
Figure 2 Functional gene expression in vitro and in vivo. (a) Dox-controlled, rtTA and tTA dependent gene activation in rat organotypic 
hippocampal slices infected with two viruses as depicted in the images above (scale bar 500 μm). With the rtTA system, tdTOM expression 
was undetectable in the absence of Dox (left panel, but it was robust with Dox (middle panel). With the tTA system, however, there was very 
strong tdTOM expression in the absence of Dox (right panel). (b) Firefly luciferase activity measurements of lysates from infected organotypic 
hippocampal slices treated with or without Dox. The mean of the luciferase activity in the absence of Dox was equated to 1. The data shown are 
mean of 4 independent infected organotypic slices and expressed as relative light units (RLU; fLUC/rLUC ± SEM). (c) In vivo bioluminescence 
in the somatosensory cortex in two mice infected with eLUC gene under control of a human hSYN promoter. Bioluminescence signal was 
detectable only after intraperitoneal injection of D-luciferin.
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inactivation (with rtTA), cortex and hippocampus of mice 
from these two groups (10 mice per group) were injected 
with a three-virus cocktail. Two weeks after virus injection, 
a single dose of Dox was delivered by a single intraperito-
neal (i.p.) injection into tTA (10 μg/g body weight) and rtTA 
(30 μg/g body weight) mice, and RLU activity was mea-
sured from brain lysates on day 0, 2, 4, 8, and 16 (two mice 
per time point and four brain samples per mouse). With a 
single i.p. Dox injection, tTA-dependent gene expression 
was switched “off” and “on” after 2 and 6 days, respec-
tively (Figure 4c). The rtTA system, gene expression was 
switched “on” and “off” after 2 and 6 days, respectively 
(Figure 4d).
For repeated on/off gene expression cycles, 8 tTA and 8 
rtTA mice were placed into four separate groups, and treated 
with Dox by a single i.p. injection (10 μg/g body weight of Dox 
for tTA mice and 30 μg/g body weight of Dox for rtTA mice). In 
the case of tTA mice, it took 2 days to switch-off gene expres-
sion by Dox, and after Dox clearance from the brain gene 
expression was fully “on” after 6 days. The rtTA showed the 
reverse; in 2 days gene expression was fully switched-on by 
a single i.p. Dox and switched-off after 6 days (Figure 4e,f).
Discussion
We have generated two recombinant rAAVs with tet con-
trolled genetic switches for long-term, inducible and reversible 
regulation of gene expression in neurons. The fLUC and the 
tdTOM genes were placed under a bidirectional tet promoter 
(P
tetbi), allowing for Dox-controlled, tTA- and rtTA-dependent 
regulated gene expression. The fLUC protein has a short 
half-life of roughly 2–4 hours and a large dynamic range that 
is five orders of magnitude. The LUC activity assay is highly 
sensitive, with minimal background activity, and is ideally 
suited for quantitative measurement of gene expression.
We characterized our two-virus approach to determine the 
time course of gene activation and inactivation in the mam-
malian brain. Our results show that both tTA and rtTA sys-
tems provide about 12-fold change in gene regulation. With 
the tTA system, gene expression (without Dox) is enabled 
from the very beginning. Although Dox treatment terminates 
gene transcription within minutes, the preexisting fLUC pro-
tein, for example, with its intrinsic half-life time of a few hours, 
will reach undetectable background levels in about 48 hours. 
With the tTA system, when it is desired that to keep gene 
expression switched-off, Dox must be constantly adminis-
tered. However, upon Dox removal, gene expression can be 
switched-on in about a week. This slow time course is due 
to slow Dox clearance from the brain. With the rtTA sys-
tem, on the other hand, gene expression can be rapidly and 
fully switch-on within 24 hours, but it takes about a week to 
switch-off gene expression, again due to slow Dox clearance 
from the brain. These results clearly show that the tTA and 
rtTA systems are highly complementary and can be flexibly 
applied to investigate specific biological processes, and they 
are also highly suited for gene therapy applications. Previous 
studies have shown that controlling the amounts of Dox lev-
els allow for graded control of gene expression, demonstrat-
ing that the tet systems operate as a rheostat.33 However, the 
rheostat can be converted to on/off switches, when transac-
tivator is combined with a repressor.34 These features allow 
for flexible application of the tet systems for biological studies.
The Ptetbi vectors are intrinsically leaky. Although this leaki-
ness is minimal, it can produce enough gene-product to inter-
fere with cell physiology. The internal terminal repeat (ITR) 
of rAAVs have potential enhancer-like activity.6,32 Previously, 
we discovered that two oppositely oriented DNA sequences 
flanking the Ptetbi, insulate the Ptetbi from the ITR. However, 
removal of one such DNA sequence (a gene, for example) 
brings the ITR very close to the Ptetbi, thereby increasing 
Dox-independent expression or leakiness.6,32 In our current 
study, we have observed that the minimal leakiness of a 
Figure 3 Dox-controlled, inactivation (tTA) and activation 
(rtTA) time courses, and regulated gene expression in vitro. 
(a,b) Time course of Dox-controlled, tTA-dependent luciferase 
activity in virus-infected dissociated primary neurons. The cells were 
infected with either the tTA system (three viruses; AAV-hSYN-tTA2, 
AAV-Ptetbi-fLUC/tdTOM, and AAV-hSYN-rLUC) or the rtTA system 
(three viruses; AAV-hSYN-rtTA2-nM2, AAV-Ptetbi-fLUC/tdTOM, 
and AAV-hSYN-rLUC). Dox-induced (1 μg/ml), time course of gene 
inactivation (with the tTA system) and gene activation (with the rtTA 
system). fLUC/rLUC activity ratios were calculated from cell lysates 
harvested at the different time points after Dox treatment, and fLUC/
rLUC activity ratios ± SEM were calculated from four independent 
slices beginning at time 0 up to 2,880 minutes. With tTA and rtTA, the 
mean of the luciferase activities at time point 2,880 and 0 (shown in 
minutes) were used as baseline, respectively. (c,d) Repeated cycles 
of gene activation and inactivation in dissociated primary neurons 
with addition of Dox (+ sign) and removal of Dox (− sign). Serial 
Dox addition and removal allowed for ON/OFF cycles testing if the 
systems. For the tTA and rtTA systems, fLUC/rLUC activity ratios 
were measured and data calculated as mean ± SEM and displayed 
here as relative light units (RLU) at time point (day 2) and time point 
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rAAV-Ptetbi can be substantially decreased by reducing the 
responder virus (rAAV-Ptetbi) titer.
We have demonstrated here that our rAAV-based approach 
is highly suitable for long-term regulated gene expression 
in living mammals. It should be pointed out that a previous 
study elegantly demonstrated the use of a single rAAV sys-
tem, harboring a transactivator (tTA or rtTA) together with a 
Ptet for regulated gene expression.
35 However, due to the lim-
ited cloning capacity of the rAAVs, a single rAAV approach 
can accommodate small DNA sequence lengths, which sub-
stantially limits the utility of a single virus approach for many 
applications. Our two rAAV approach on the other hand pro-
vides a flexible solution to simultaneously control the expres-
sion of multiple genes.
In summary, we have characterized a two-virus approach 
equipped with Dox-controlled genetic switches for regulated 
gene expression in the mammalian brain. The implementa-
tion of our flexible rAAV based inducible and reversible gene 
expression approach has a promising future for neurosci-
ence and biomedical studies, and gene therapy applications.
Materials and methods
Animal welfare. All experiments were performed in accor-
dance with the animal welfare guidelines of the Max Planck 
Society and approved by the local authorities (Regierungsprä-
sidium Karlsruhe). We housed 6–10-week-old C57BL/6 wild-
type and NMRI albino mice under standard conditions in a 
12-hour light/dark cycle in Makrolon cages type 2A with food 
and water.
Plasmid constructs. In the current study, we generated new 
rAAV plasmids, (i) pAAV-P
tetbi-fLUC/tdTOM and (ii) pAAV-
hSYN-eLUC (enhanced luciferase)36 and (iii) pAAV-hSYN-
rLUC. The other plasmids (pAAV-hSYN-tTA, pAAV-hSYN-rtTA, 
and pAAV-hSYN-EGFP) were described previously.6,37 
To generate the plasmid pAAV-Ptetbi-fLUC/tdTOM, fire-
fly luciferase gene (1.6 kb fragment) was excised from the 
plasmid pB1-5 (ref. 28) with Pst1/Xba1, blunted and subse-
quently ligated into a HindIII/Sph1 blunted plasmid pAAV- 
Ptetbi-iCre/tdTOM, replacing iCre with fLUC. Similarly, the 
plasmid pAAV-hSYN-rLUC was generated by blunt-end 
ligation by replacing the EGFP from pAAV-hSYN-EGFP 
(BamHI/HindIII) with a 947 bp rLUC fragment from the plas-
mid pRL-CMV (Nhe/Xba1). To generate the plasmid pAAV-
hSYN-eLUC, the enhanced luciferase gene (eLUC) including 
SV40pA was excised from the plasmid peLUC-test (a gift from 
Dr. Nakajima) using EcoR1/BamH1 and a 1.9 kb fragment 
was ligated into the vector pAAV-hSYN-vector (without tTA) 
using EcoR1/BamH1. To generate the plasmid pAAV-Ptetbi-
eLUC/Venus, the 1.6 kb eLUC fragment was amplified by 
PCR from the plasmid peLUC with the forward primer EcoRV 
5′-AATTCGATATCGAATTCCTGCAGCCCAC-3′ and the 
reverse primer SpeI 5′-TGTCTGACTAGTGGCGGCCGCTCT 
AGATTA-3′. The PCR generated fragment was cloned into 
the vector pAAV-Ptetbi-IKK2DN/Venus (unpublished plasmid), 
Figure 4 Dox doses, inactivation (tTA) and activation (rtTA) 
time courses, and Dox-controlled regulated gene expression 
in vivo. Wild-type mice were injected with the tTA system (three 
viruses; AAV-hSYN-tTA2, AAV-Ptetbi-fLUC/tdTOM, and AAV-hSYN-
rLUC) or the rtTA system (three viruses; AAV-hSYN-rtTA2-nM2, 
AAV-Ptetbi-fLUC/tdTOM, and AAV-hSYN-rLUC). For each time 
point, measurements were made from 12 cortical and hippocampal 
extracts from three independently injected mice, and fLUC/rLUC 
activity ratios were measured and data calculated as mean ± SEM 
and displayed here as relative light units (RLU). (a,b) Mice were 
treated with different concentrations of Dox per gram body weight 
(ranging from 0 to 100 μg/g). For the tTA and rtTA systems, Dox-
treated (100 μg/g) and Dox-untreated mean luciferase/renilla ratios 
were used as baselines, respectively. (c,d) Time course (days) for 
tTA-dependent gene re-activation with a single intraperitoneal Dox 
injection (10 μg/g, P < 0.0001) and rtTA-dependent gene inactivation 
after a single intraperitoneal Dox injection (30 μg/g, P < 0.0001). 
(e,f) With the tTA system, gene inactivation (single Dox i.p.) and 
reactivation (after single Dox i.p.) was 2 and 6 days, respectively. 
With the rtTA system, gene activation (single Dox i.p.) and 
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by removing IKK2DN with EcoRV and SpeI and replacing it 
with eLUC to generate the plasmid pAAV-Ptetbi-eLUC/Venus.
Preparation and purification of rAAVs via Heparin column. 
Recombinant adeno-associated viruses (rAAVs) serotype 
1 and 2 were generated by cotransfection of HEK293 cells 
and purified by modified heparin column purification as 
described.6 In brief, plasmids corresponding to the various 
rAAVs used in this study were individually cotransfected with 
pDp1 and pDp2 (ratio 2:1:1) helper plasmids in HEK293 cells 
by the calcium-phosphate method.38 Forty-eight hours after 
transfection, cells were harvested into a 50 ml falcon tube 
followed by centrifugation at 1,000 rpm for 15 minutes. The 
cell pellet was resuspended in 45 ml of 150 mmol/l NaCl, 20 
mmol/l Tris.HCl (pH 8.0), frozen in liquid nitrogen and stored 
at −70 °C. Cells were thawed at room temperature (RT) and 
incubated at 37 °C with 40 U/ml of benzonase and 0.5% 
NaDOC for 60 minutes with frequent mixing. Lysed cells were 
centrifuged and frozen at −70 °C for at least a few hours and 
subsequently thawed and centrifuged at 3,900 rpm for 15 
minutes, supernatant collected and frozen at −70 °C over-
night. Frozen supernatant was thawed and spin for 15 min-
utes at 4,000 rpm. The cleared supernatant was run through 
a pre-equilibrated 1 ml heparin column. The HiTrap Heparin 
HP column  (GE Healthcare Bio-Sciences AB, Uppsala, Swe-
den) was serially washed with 20 ml of 100 mmol/l NaCl, 20 
mmol/l Tris.HCl (pH 8), 1 ml of 200 mmol/l NaCl, 20 mmol/l 
Tris.HCl (pH 8) and 1 ml of 300 mmol/l NaCl, 20 mmol/l Tris.
HCl (pH 8). The virus was eluted from the heparin column 
serially with 1.5 ml of 400 mmol/l NaCl, 20 mmol/l Tris.HCl, 
3ml of 450 mmol/l NaCl, 20 mmol/l Tris.HCl (pH 8) and 1.5ml 
of 500 mmol/l NaCl, 20 mmol/l Tris.HCl (pH 8). The eluate 
was concentrated in a 15 ml Amicon Ultra (100,000 cut-off) 
concentrator (Merck Millipore, Darmstadt, Germany). The 
virus was concentrated further into a final volume of 250 μl 
and filtered through 0.2 μm Acrodisc filter (Merck Millipore, 
Darmstadt, Germany).
Virus infection of hippocampal organotypic slices and dis-
sociated neurons. Organotypic slices were prepared as 
described previously39 and slices were infected with 500 nl 
of virus cocktails by local application on individual slices. The 
two different virus cocktails are as follows: the tTA system 
(rAAV-Ptetbi-fLUC/tdTOM + rAAV-hSYN-rLUC + rAAV-hSYN-
tTA) and the rtTA system (rAAV-Ptetbi-fLUC/tdTOM + rAAV-
hSYN-rLUC + rAAV-hSYN-rtTA). Media were changed 5 days 
after infection, and subsequently replaced every 3 days. Dis-
sociated neurons on the other hand, were infected by adding 
1 μl of the virus cocktail into 1 ml of medium. Two weeks of 
virus infection, brain slices were lysed for quantitative lucifer-
ase activity measurements or fixed for fluorescent imaging 
of tdTOM.
Quantifying luciferase gene activity in dissociated neurons. 
Dissociated primary neurons were infected with a tTA virus 
cocktail or rtTA virus cocktails. Two weeks later, cells infected 
with the tTA and rtTA systems were incubated for 48 hours 
either without or 1 μg/ml of Dox, respectively. Subsequently, 
cells were lysed with 100 μl of passive lysis buffer and 20 
μl of the lysates were used for measuring firefly and renilla 
luciferase activities. For the repeated cycle of gene activa-
tion and inactivation, dissociated primary neurons in 24-well 
plates were infected with tTA and rtTA systems. Two weeks 
after infection, cells were put into five groups each group con-
sisting of four wells. Each group was incubated with or without 
Dox over 48 hours. The Dox-treated medium was replaced 
with a conditioned medium without Dox also for another 
48 hours. This was repeated for five cycles of Dox addition or 
withdrawal. The removal of Dox was done by washing three 
times with conditioned medium without Dox. At the end of 
two cycles, cells were harvested for luciferase assay. The 
firefly luciferase (fLUC) and renilla luciferase (rLUC) assays 
were performed sequentially in one reaction tube according 
to the manufacturer’s instruction (Promega Corporation, Wis-
consin). To normalize gene activity, fLUC/rLUC mean ratios 
were calculated as relative light units (RLU) ± SEM, and for 
each time point, measurements were performed from four 
independent cell lysates. For detailed dual luciferase reporter 
assay protocol, refer to Dual-Luciferase Reporter Assay 
System protocol instructions for use of products e1910 and 
e1960 (Promega Corporation).
Stereotactic virus injection into the mouse brain. Six- to 
10-week-old C57BL/6 and NMRI albino mice were deeply 
anesthetized (ketamine 100 mg/kg, and xylazine 5 mg/kg) 
and secured in a Kopf stereotaxic setup (Kopf Instruments, 
California). The surgical procedure was started only after ani-
mals no longer responded to tail or paw pinch. Throughout 
the surgery, animals were kept on a heating pad to prevent 
hypothermia. Cream (Bepanthen, Bayer, Leverkusen, Ger-
many) was applied to the eyes of mice to prevent dehydra-
tion. The foreskin on the skull was cut open to expose the 
skull. With the help of a drill, small holes (about 50–100 μm) 
were drilled into the head of the mice at different coordinates. 
Approximately 300 nl of viral cocktail was injected via glass 
pipette (tip diameter 10–20 μm) into each brain region. For 
in vivo bioluminescence imaging, mice were injected in the 
motor cortex. For in vivo luciferase activity measurement, 
mice were injected in the somatosensory cortex and in the 
hippocampus of both brain hemispheres. After injection, the 
skin was sutured and the wound disinfected. Newly injected 
mice were kept on heating blocks at 37 °C until they woke 
up and were fed wet food. The coordinates used for the dif-
ferent injections with reference to the bregma are as follows: 
for hippocampus (−1.70 mm bregma, 1.5 mm lateral, 1.5 mm 
deep), for motor cortex (0.5 mm bregma, 1 mm lateral, 500 
μm deep) and for somatosensory cortex (−1.70 mm bregma, 
1.5 mm lateral, 500 μm deep). To avoid postoperative dehy-
dration, mice were injected with physiological saline solution. 
To reduce moderate acute pain, buprenorphine (Buprenex, 
0.1 μg/g body weight) was injected after the surgical proce-
dure. Mice were placed on a heating-pad while recovering 
from surgery.
Quantifying luciferase gene activity in brain tissues. To mea-
sure luciferase activities from brain lysates, wild-type mice 
were injected with the tTA system (rAAV-P
tetbi-fLUC/tdTOM 
+ rAAV-hSYN-rLUC + rAAV-hSYN-tTA) and the rtTA sys-
tem (rAAV-Ptetbi-fLUC/tdTOM + rAAV-hSYN-rLUC + rAAV-
hSYN-rtTA). Two weeks after virus injection, mice were either 
www.moleculartherapy.org/mtna
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injected with Dox (rtTA injected mice) or without (tTA injected 
mice), and 48 hours later mice were anaesthetized with isoflu-
rane and decapitated or virus infected brain regions (somato-
sensory cortex and hippocampus) were carefully dissected 
and frozen in liquid nitrogen. Brain extracts were prepared 
and later sonicated in 200 μl PBS and 20 μl of the extract 
was used to measure firefly and renilla luciferase activities as 
described above.
Bioluminescence imaging in vivo. Bioluminescence imaging 
was performed with an EM-CCD Digital camera C9100-13 
(Hamamatsu Photonics Deutschland GmbH, Herrsching am 
Ammersee, Germany) in combination with a dark box (AEQUO-
RIA MDS) (Hamamatsu Photonics Deutschland GmbH, 
Herrsching am Ammersee). At the beginning of the experiment, 
BALB/c mice were stereotactically injected with rAAV-hSYN-
eLUC into the cortex of the right brain hemisphere. After recov-
ery from surgery the animals were anesthetized with a mixture 
of ketamine (65 μg/g) and xylazine (14 μg/g) by i.p injection. To 
avoid dehydration, all mice were injected with 500 μl of physi-
ological saline (0.9 % NaCl). Furthermore, the animals were 
i.p. injected with an aqueous solution of D-luciferin (300 μg/g). 
Right after the last injection, mice were placed on a stage in the 
Hamamatsu dark box. At first, a bright field image was taken for 
later analysis followed by bioluminescence recording using the 
streaming mode (six images possible with an exposure time of 
10 minutes each). All data was recorded with the aid of Hokawo 
imaging software version 2.1, also provided by Hamamatsu 
Photonics Deutschland GmbH, Herrsching am Ammersee.
Immunostaining with NeuN antibody. Immunostaining was car-
ried out on wild-type mice or rat organotypic slices infected 
with a tTA system (rAAV-P
tetbi-fLUC/tdTOM and rAAV-hSYN-
tTA). In brief, mice were perfused with warm PBS and fixed in 
4% paraformaldehyde in 1× phosphate buffered saline (PBS) 
prior to decapitation. Brains were removed and postfixed in 4% 
paraformaldehyde at 4 °C overnight, followed by embedding in 
2.5% agarose. Coronal sections with 60–100 μm in thickness 
were prepared by vibratome slicing and stored in PBS 4 °C. 
Tissues were blocked in 4% normal goat serum supplemented 
with 1% bovine serum albumin (BSA), 0.3% Triton X-100, and 
incubated overnight at room temperature in anti-NeuN (mouse 
monoclonal, Chemicon, California) primary antibody diluted in 
1× PBS, 1% (BSA), and 1% normal goat serum/0.3% Triton 
X-100. The next day, tissues were washed twice in 1× PBS/0.3% 
BSA/0.1% Triton X-100 followed by anti-mouse FITC secondary 
antibody (1:200, Jackson Immuno Research, Pennsylvania) for 
1 hour at room temperature. Slices were washed 2× in PBS 
and mounted with Aqua Poly/Mount on glass slides with cover 
slips. Immunostained sections were analyzed with an Axiovert 
200 M confocal microscope with LSM 5 PASCAL (Zeiss, Jena, 
Germany) coupled to 543 nm HeNe and 450–530 nm Argon 
lasers (Lasos Lasertechnik GmbH, Jena, Germany).
Statistical analysis. All data are presented as mean ± stan-
dard error of the mean. Figure 2b was analyzed with t-tests 
P < 0.0001. Multiple group comparisons were performed with 
one-way analysis of variance with P < 0.05 is considered 
significant.
Supplementary material
Figure S1. Neuron-specific gene expression.
Figure S2. Firefly luciferase activity in relative light units.
Figure S3. Enhanced firefly luciferase expression using 
 different rAAV expression systems.
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